NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $13.76 -0.75 (-5.17%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$14.00 +0.24 (+1.74%) As of 04:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARQT alerts:Sign Up Key Stats Today's Range$13.57▼$14.3850-Day Range$12.59▼$17.2952-Week Range$6.99▼$17.75Volume2.00 million shsAverage Volume2.29 million shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$18.80Consensus RatingModerate Buy Company OverviewArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More… Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 453rd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.33) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 14.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.70% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.70% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 5.29%, indicating that investor sentiment is decreasing significantly. News and Social Media3.6 / 5News Sentiment1.39 News SentimentArcutis Biotherapeutics has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Arcutis Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows12 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $632,162.00 in company stock.Percentage Held by InsidersOnly 9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Stock News HeadlinesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $104,835.57 in StockMay 21 at 6:44 AM | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $52,606.89 in StockMay 10, 2025 | insidertrades.comBanks aren’t ready for this altcoin—are you?Bitcoin Just Made Headlines — Here’s Where I’m Putting My Money Next There's a little-known crypto project sitting right in the sweet spot of all these trends and based on what I'm seeing — it could run even harder than BTC.May 22, 2025 | Crypto 101 Media (Ad)Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 5,030 Shares of StockMay 6, 2025 | insidertrades.comNew Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical PracticeMay 15, 2025 | globenewswire.comArcutis Biotherapeutics: Zoryve foam treatment resulted in major improvementsMay 9, 2025 | finance.yahoo.comArcutis Biotherapeutics, Inc.: Arcutis Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finanznachrichten.deArcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association DermatologyMay 7, 2025 | globenewswire.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $13.93 at the start of the year. Since then, ARQT shares have decreased by 1.2% and is now trading at $13.76. View the best growth stocks for 2025 here. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. The business had revenue of $65.85 million for the quarter, compared to analyst estimates of $64.80 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 119.11% and a negative net margin of 140.97%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Top institutional investors of Arcutis Biotherapeutics include Jennison Associates LLC (9.53%), Vanguard Group Inc. (5.72%), American Century Companies Inc. (1.39%) and GW&K Investment Management LLC (1.27%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Orbimed Advisors Llc, David W Osborne, Masaru Matsuda, Larry Todd Edwards, David Joseph Topper, Howard G Welgus, Patrick Burnett, Patricia A Turney, Scott L Burrows and Terrie Curran. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings5/06/2025Today5/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Stock Price Target$18.80 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+36.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-140.97% Pretax Margin-140.67% Return on Equity-119.11% Return on Assets-45.95% Debt Debt-to-Equity Ratio0.67 Current Ratio2.46 Quick Ratio2.38 Sales & Book Value Annual Sales$212.82 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book14.64Miscellaneous Outstanding Shares119,202,000Free Float105,926,000Market Cap$1.64 billion OptionableOptionable Beta1.87 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ARQT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.